An Early Phase 1 interventional study of Linaclotide 290 micrograms and Lactose placebo pill in Cystic Fibrosis (CF), sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University of Nottingham · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 130th largest by planned enrollment of the 186 interventional ones that give a count, is one of 8 that started in 2026, is one of 25 in phase 1, reaches primary completion later than 12 of the 31 other live ones, and was the 228th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Aimmune Nestlé Health Science US R&D, LLC · Sites in United Kingdom, United States, Bulgaria and 4 more countries
Ages 18–85
Imperial College London · Sites in United Kingdom
Healthy volunteers
Alexander Horsley · Sites in United Kingdom
Ages 16+
Papworth Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 53 · Phase 3 62 · Phase 4 9
First in 2001; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 26 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 69 across the 186 interventional studies, 79 across the 49 observational. Of the 186 that completed or were terminated, 83 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 236 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 5 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Cystic Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT07780344University of NottinghamMRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO) | 2027-05 |
| NCT07879651Royal Brompton & Harefield NHS Foundation TrustSPutum Induction and Nebuliser deviCEs for Patients With CF | 2027-06 |
| NCT07559175Aimmune Nestlé Health Science US R&D, LLCA Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Linaclotide is a medicine used to treat constipation and irritable bowel syndrome with constipation (IBS-C). It works by acting on the surface of the gut lining, where it increases the movement of salt and water into the bowel. This softens stools, makes them easier to pass, and can also reduce gut pain
One advantage of linaclotide is that, unlike some natural substances in the gut, it is stable and can act throughout the intestine. Studies in animals show that it has the strongest effect in the upper small intestine, but it may act in other parts of the bowel as well. In people, however, it is not yet clear whether linaclotide mainly works in the small intestine or in the large intestine (colon). Knowing this is important, because it could help the investigators understand whether linaclotide might also be useful in other conditions, such as cystic fibrosis, where the gut does not handle fluid properly.
Linaclotide is taken as a capsule, but less than 1% is absorbed into the bloodstream. Instead, it stays in the gut, where it is broken down into smaller active parts. This means both the small intestine and colon may be exposed to its effects.
Until now, it has been hard to study this because traditional methods only measure one part of the gut at a time. A team at the University of Nottingham has developed MRI scanning methods that can safely and non-invasively measure water content in the small intestine and colon.
The aim of this pilot study is to use MRI in healthy volunteers to see exactly where linaclotide acts. This knowledge will help optimise future studies in conditions such as cystic fibrosis.
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. In CF, defective CFTR may lead to various clinical effects on the gastrointestinal (GI) system; indeed, many CF patients report significant GI symptoms, with the most frequent being attributable to the lower GI tract, including bloating, flatulence, abdominal pain, and borborygmi. Moreover, constipation is another prevalent GI symptom in CF patients. It is estimated that 10-57% of CF patients report constipation symptoms, with an even higher prevalence (approximately 73%) in adults over the age of 30. Symptoms such as constipation are hypothesised to occur due to decreased luminal fluid content resulting from a reduction in anion flow, which ultimately leads to increased amounts of viscous mucus and slowed transit of intestinal contents. Presently, these GI symptoms in CF patients are often treated with laxatives and enemas, and in some cases surgical treatment, which can be uncomfortable and invasive, suggesting that alternative treatments are required.
Linaclotide, a drug approved for safe use across Europe and in the UK, is a synthetic analogue of uroguanylin that activates guanylate cyclase-C (GC-C) receptors located on the luminal surface of intestinal epithelial cells. Activation of GC-C increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates cGMP-dependent protein kinase II (PKGII) and protein kinase A (PKA). Collectively, these kinases activate CFTR, leading to chloride and water secretion into the intestinal lumen. In parallel, elevated cGMP inhibits the sodium-hydrogen exchanger 3 (NHE3), thereby reducing sodium and water absorption. Together, these actions promote fluid secretion and accelerate intestinal transit, leading to linaclotide being commonly prescribed for the treatment of chronic idiopathic constipation and irritable bowel syndrome with chronic constipation (IBS-C).
Meta-analyses confirm linaclotide's clinical benefit in chronic idiopathic constipation and IBS-C; however, its role in CF remains uncertain, though anecdotal reports and animal models suggest therapeutic potential. Linaclotide has less than 1% systemic bioavailability and is degraded in the upper small bowel by carboxypeptidases to an active metabolite, with a small proportion of the administered dose recovered in stool, providing exposure throughout the small and large intestine. However, the primary site of action in humans remains undefined.
Traditional perfusion methods provide only segmental information, limiting assessment of the whole intestine. By contrast, magnetic resonance imaging (MRI) enables non-invasive evaluation of gastrointestinal water content across multiple regions. The Nottingham group has validated MRI techniques for quantifying small bowel water content and assessing colonic chyme hydration via T1 mapping. These methods have been successfully applied to study the effects of various pharmacological agents on gastrointestinal function.
Aim: To define the site of action of linaclotide in healthy volunteers using MRI. Identifying the regional effects of linaclotide will help optimise its future evaluation in CF patients. Based on clinical observations in constipation, stool effects emerge within seven days; however, the investigators hypothesise that small bowel changes occur within 1-2 hours of dosing. Therefore, a one-day pre-dosing regimen is expected to elicit a measurable effect on both the small bowel and colon while minimising participant burden.
Subjects will take 290ug linaclotide /placebo on the day prior to study day (day -1) and on the study day
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant is willing and able to give for participation in the study
Not currently taking any medications (except for selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral pill).
Aged between 18-60 years.
Ability to conform to the study protocol, including overnight fasting, dietary and lifestyle restriction, administering linaclotide and placebo intervention, MRI scanning, consuming the rice pudding/blue dye meal, and rating stool frequency and appearance.
Exclusion Criteria:
to MRI scanning (i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, unable to lie flat and relatively still for less than 5 minutes.)
Pregnancy, lactating, or planning pregnancy during the investigation declared by candidate.
History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function.
Reported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix).
Intestinal stoma.
Any medical condition that may potentially compromise participation in the study e.g., known food intolerance to rice pudding, known contraindication to the oral administration of linaclotide or placebo.
Has a (BMI) value less than 18.5 or greater than 35.
Will not agree to follow dietary and lifestyle restrictions required.
Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study.
Participants who are currently (or in the past 3 months) taking antibiotics or probiotics as these may impact GI function.
Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM.
Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse.
Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
290 mcg linaclotide across 2 days
Drug: Linaclotide 290 micrograms
Lactose placebo
Drug: Lactose placebo pill
290 mcg, 2 days dosing, oral capsule form
Placebo form, oral capsules identical to linaclotide
Small bowel water content
Area under curve (AUC) 0-360 minutes Water content in small bowel as assessed by MRI (mL)
Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose
Colon water content
Area under curve (AUC) 0-360 min Water content in the ascending colonic region as assessed by MRI (mL)
Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose
Colonic regional segmental volumes
Total volume of regional colonic segments (ascending, transverse, descending, sigmorectal) as assessed by MRI (mL) at each time point.
Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose
Changes in stool consistency
Stool consistency rated using Bristol stool scale (type 1-7; 7 being watery stool).
Time frame: 2 days before intervention, 5 days post-intervention
Changes in whole gut transit time (WGTT)
Assessed by time to stool discolouration following administration of blue dye paste.
Time frame: 1 day post-intervention
Gastrointestinal symptom rating
Assessing the severity of common gastrointestinal symptoms (flatulence / gas passage, diarrhoea / loose stool, bloating, abdominal pain) via Likert-type scale: 0 = not at all 1. = mild (distinct but negligible) 2. = moderate (annoying) 3. = severe (disabling
Time frame: 2 days pre-intervention and 5 days post-intervention
Changes in stool frequency
Frequency (per day) of bowel movements (number with exact time)
Time frame: 2 days before starting intervention and for 5 days post intervention
Small bowel motility
Maximum motility score (A.U) of the small bowel as assessed by MRI
Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose
Plan to share: Undecided
Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.
Of 62 phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linaclotide